ADMS Insider Trading Activity and SEC Form 4 Filings
ADMS insider trading summary
No open-market insider purchases or sales of Adamas Pharmaceuticals Inc (ADMS) have been reported on SEC Form 4 in the past 12 months.
Latest ADMS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 21, 2021 | Vijay Shreedhar | Chief Commercial Officer | Sell | $32K (6,200 @ $5.16) |
| Jun 7, 2021 | Martha J Demski | Director | Sell | $10K (2,000 @ $5.17) |
| Mar 22, 2021 | Vijay Shreedhar | Chief Commercial Officer | Sell | $6K (1,051 @ $5.50) |
| Mar 22, 2021 | Christopher B Prentiss | Chief Financial Officer | Sell | $13K (2,422 @ $5.48) |
| Mar 11, 2021 | Spyridon Papapetropoulos | Director | Buy | $30K (5,975 @ $5.06) |
| Feb 1, 2021 | Vijay Shreedhar | Chief Commercial Officer | Sell | $29K (4,514 @ $6.39) |
| Feb 1, 2021 | Christopher B Prentiss | Chief Financial Officer | Sell | $24K (3,821 @ $6.36) |
| Jan 20, 2021 | Christopher B Prentiss | Chief Financial Officer | Sell | $12K (2,630 @ $4.41) |
| Nov 2, 2020 | Christopher B Prentiss | Chief Financial Officer | Sell | $7K (2,050 @ $3.21) |
| Jan 21, 2020 | Christopher B Prentiss | Chief Financial Officer | Sell | $8K (1,269 @ $5.92) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.